Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in approximately 15–20% of gastric adenocarcinoma (GC) patients. In 2010, the landmark ToGA trial established the combination of trastuzumab plus chemotherapy as the first-line standard of care for HER2-positive GC patients with advanced disease. However, subsequent studies on HER2 targeted therapies in this setting failed to meet their primary endpoints, and not all HER2-positive GC patients benefit from targeted approaches. More recently, novel HER2-directed treatments have been investigated, including trastuzumab deruxtecan (T-Dxd); following the results of the DESTINY-Gastric01 study, T-Dxd received its first U.S. Food and Drug Administration (FDA) approval on 15 January 2021 for the treatment of adults with unresectable, locally advanced, or metastatic GC who have received a prior trastuzumab-based regimen. In this review, we discuss the current HER2-targeted treatments for GC in the advanced disease setting, mainly focusing on emerging new treatments and future research directions.

Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? / Ricci A.D.; Rizzo A.; Llimpe F.L.R.; Fabio F.D.; De Biase D.; Rihawi K.. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 13:7(2021), pp. 1664.1-1664.9. [10.3390/cancers13071664]

Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift?

Ricci A. D.;Rizzo A.
;
De Biase D.;Rihawi K.
2021

Abstract

Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in approximately 15–20% of gastric adenocarcinoma (GC) patients. In 2010, the landmark ToGA trial established the combination of trastuzumab plus chemotherapy as the first-line standard of care for HER2-positive GC patients with advanced disease. However, subsequent studies on HER2 targeted therapies in this setting failed to meet their primary endpoints, and not all HER2-positive GC patients benefit from targeted approaches. More recently, novel HER2-directed treatments have been investigated, including trastuzumab deruxtecan (T-Dxd); following the results of the DESTINY-Gastric01 study, T-Dxd received its first U.S. Food and Drug Administration (FDA) approval on 15 January 2021 for the treatment of adults with unresectable, locally advanced, or metastatic GC who have received a prior trastuzumab-based regimen. In this review, we discuss the current HER2-targeted treatments for GC in the advanced disease setting, mainly focusing on emerging new treatments and future research directions.
2021
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift? / Ricci A.D.; Rizzo A.; Llimpe F.L.R.; Fabio F.D.; De Biase D.; Rihawi K.. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 13:7(2021), pp. 1664.1-1664.9. [10.3390/cancers13071664]
Ricci A.D.; Rizzo A.; Llimpe F.L.R.; Fabio F.D.; De Biase D.; Rihawi K.
File in questo prodotto:
File Dimensione Formato  
cancers-13-01664.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 4.14 MB
Formato Adobe PDF
4.14 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/860008
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 54
social impact